moxifloxacin has been researched along with e-z cinnamic acid in 3 studies
| Studies (moxifloxacin) | Trials (moxifloxacin) | Recent Studies (post-2010) (moxifloxacin) | Studies (e-z cinnamic acid) | Trials (e-z cinnamic acid) | Recent Studies (post-2010) (e-z cinnamic acid) |
|---|---|---|---|---|---|
| 3,157 | 552 | 1,690 | 1,102 | 2 | 637 |
| Protein | Taxonomy | moxifloxacin (IC50) | e-z cinnamic acid (IC50) |
|---|---|---|---|
| Poly [ADP-ribose] polymerase tankyrase-1 | Homo sapiens (human) | 0.685 | |
| Poly [ADP-ribose] polymerase tankyrase-2 | Homo sapiens (human) | 0.685 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Bellman, K; Knegtel, RM; Settimo, L | 1 |
| Das, SC; Eedara, BB; Price, JR; Rades, T; Tucker, IG; Zujovic, ZD | 1 |
| Akbar, N; Jabri, T; Kawish, M; Khan, NA; Shah, MR; Siddiqui, R | 1 |
3 other study(ies) available for moxifloxacin and e-z cinnamic acid
| Article | Year |
|---|---|
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |
Crystalline adduct of moxifloxacin with trans-cinnamic acid to reduce the aqueous solubility and dissolution rate for improved residence time in the lungs.
Topics: Antitubercular Agents; Cinnamates; Crystallization; Lung; Moxifloxacin; Permeability; Solubility | 2019 |
Enhancing efficacy of existing antibacterials against selected multiple drug resistant bacteria using cinnamic acid-coated magnetic iron oxide and mesoporous silica nanoparticles.
Topics: Anti-Bacterial Agents; Cefixime; Cinnamates; Escherichia coli; Ferric Compounds; Humans; Lactate Dehydrogenases; Magnetic Phenomena; Methicillin; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Moxifloxacin; Nanoparticles; Prospective Studies; Silicon Dioxide; Sulfamethoxazole | 2022 |